{"id":893352,"date":"2025-10-07T10:25:35","date_gmt":"2025-10-07T14:25:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/"},"modified":"2025-10-07T10:25:35","modified_gmt":"2025-10-07T14:25:35","slug":"creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/","title":{"rendered":"Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs"},"content":{"rendered":"

\nRecent Issuance of U.S. Patents Covering ImmCelz\u2122 \u2014 Supercharged Regulatory T Cell Programs in Heart Failure and Type 1 Diabetes Reinforce Creative Medical\u2019s Similar Research Focus
\n<\/h2>\n
\n

PHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc.<\/strong> (NASDAQ: CELZ) (\u201cCreative Medical\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today congratulated Mary E. Brunkow, Ph.D., Fred Ramsdell, Ph.D., and Shimon Sakaguchi, M.D., Ph.D. on being awarded the 2025 Nobel Prize in Physiology or Medicine for foundational discoveries in peripheral immune tolerance and the biology of regulatory T cells (Tregs). Their work\u2014including the identification of Tregs and the central role of FOXP3\u2014reshaped modern immunology and catalyzed new treatment strategies across autoimmunity, transplantation, and cancer.<\/p>\n

In parallel with this global recognition of Treg science, Creative Medical reiterated that it has recently received two U.S. Patents for its proprietary ImmCelz\u2122 platform: (1) U.S. Patent Number 12931925B2 (expires\u00a02043-05-24) for the prevention and\/or treatment of Type 1 Diabetes by augmentation of myeloid suppressor cell activity; and (2) U.S. Patent Number 12385011B2 (expires\u00a02042-12-15) for the treatment of heart failure and\/or post infarct pathological remodeling by ex vivo reprogrammed immune cells. Both of these programs utilize the Company’s\u00a0super charged\u00a0Regulatory T cells.<\/p>\n

\u201cToday\u2019s Nobel spotlight is squarely on Tregs\u2014the same biology our ImmCelz\u2122 engine is built to harness,\u201d said Timothy Warbington, CEO of Creative Medical. \u201cWith dual patents spanning cardiometabolic disease, we believe Creative Medical is constructing an IP-fortified, category-defining regenerative immunotherapy franchise with runway to at least 2042. Our strategy is simple: translate Nobel-recognized immunology into disruptive, patient-centric procedures that may unlock durable value for patients, partners and shareholders alike.\u201d<\/p>\n

The Company\u2019s heart failure allowance protects broad methods to treat patients at risk of, or with, heart failure and post-infarct pathological remodeling using the ImmCelz\u2122 product, which is delivered via an ultra-minimally invasive outpatient procedure. In the United States alone, the treatable heart failure population exceeds five million, and more than six million patients with refractory angina may also be candidates\u2014underscoring the potential scale of impact.<\/p>\n

The Type 1 diabetes allowance supports a broad, cell-based immunotherapy approach\u2014including supercharged T regulatory cells\u2014and has been validated using cells from patients with Type 1 diabetes. This program aligns with the Company\u2019s ongoing CREATE-1 clinical trial, further reinforcing Creative Medical\u2019s focus on regenerative immunotherapy in autoimmune disease.<\/p>\n

\u201cTregs are the immune system\u2019s peacekeepers. The Nobel recognition amplifies decades of evidence that precise Treg modulation can recalibrate immunity,\u201d Warbington added. \u201cImmCelz\u2122 was engineered to reprogram a patient\u2019s own immune cells outside the body, supercharge them with optimized cell-free factors, and re-introduce them\u2014an approach designed to orchestrate repair, not just suppress symptoms. We see an expanding opportunity to deploy this platform across high-burden indications where immune over-activation and tissue damage intersect.\u201d<\/p>\n

\n About ImmCelz\u2122<\/strong>
\n
Creative Medical\u2019s ImmCelz\u2122 platform utilizes a patient\u2019s own extracted immune cells that are then \u201creprogrammed\/supercharged\u201d by culturing them outside the body with optimized cell-free factors. The cells are then re-injected into the patient from whom they were extracted. The Company believes this process endows immune cells with regenerative properties on top of their innate functions, enabling potential treatment across multiple indications.<\/p>\n

\n About Creative Medical Technology Holdings<\/strong>
\n
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company pioneering regenerative medicine solutions across multiple indications. The Company leverages cutting-edge cell therapy technologies to develop transformative treatments aimed at improving patient outcomes.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This news release may contain forward-looking statements, including, but not limited to, statements regarding the development and commercialization of the Company\u2019s therapies (including ImmCelz\u2122), market opportunities, clinical progress, strategic alternatives, and the strength of the Company\u2019s intellectual property portfolio. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties are detailed in the Company\u2019s periodic reports filed with the U.S. Securities and Exchange Commission (SEC) and available at www.sec.gov<\/u><\/a>. The Company undertakes no obligation to update forward-looking statements except as required by law.<\/p>\n

\n Nobel Prize\u00ae<\/sup><\/strong> is a registered trademark of the Nobel Foundation; use herein is for identification only and does not imply any affiliation or endorsement.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n Contact:<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Creative Medical Technology Holdings, Inc.<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n
\n IR@CreativeMedicalTechnology.com<\/u>
\n <\/a>\n <\/td>\n		\u00a0<\/td>\n<\/tr>\n
\n
\n www.creativemedicaltechnology.com<\/u>
\n <\/a>\n <\/td>\n		\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n
\n Investor Relations:<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
Devin Sullivan, Managing Director<\/td>\nDave Gentry<\/td>\n<\/tr>\n
The Equity Group Inc.<\/td>\nRedChip Companies<\/td>\n<\/tr>\n
\n
\n dsullivan@equityny.com<\/u>
\n <\/a>\n <\/td>\n		1-407-644-4256<\/td>\n<\/tr>\n
\u00a0<\/td>\n\n
\n CELZ@redchip.com<\/u>
\n <\/a>\n <\/td>\n<\/tr>\n
Conor Rodriguez<\/td>\n\u00a0<\/td>\n<\/tr>\n
Associate<\/td>\nPaul Kuntz<\/td>\n<\/tr>\n
\n
\n crodriguez@equityny.com<\/u>
\n <\/a>\n <\/td>\n		Communications Director<\/td>\n<\/tr>\n
\u00a0<\/td>\nRedChip Companies<\/td>\n<\/tr>\n
\u00a0<\/td>\n\n
\n paul@redchip.com<\/u>
\n <\/a>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n412-708-4590<\/td>\n<\/tr>\n<\/table>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Recent Issuance of U.S. Patents Covering ImmCelz\u2122 \u2014 Supercharged Regulatory T Cell Programs in Heart Failure and Type 1 Diabetes Reinforce Creative Medical\u2019s Similar Research Focus PHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (\u201cCreative Medical\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today congratulated Mary E. Brunkow, Ph.D., Fred Ramsdell, Ph.D., and Shimon Sakaguchi, M.D., Ph.D. on being awarded the 2025 Nobel Prize in Physiology or Medicine for foundational discoveries in peripheral immune tolerance and the biology of regulatory T cells (Tregs). Their work\u2014including the identification of Tregs and the central role of FOXP3\u2014reshaped modern immunology and catalyzed new treatment strategies across autoimmunity, transplantation, and cancer. In parallel with this … <\/p>\n

Continue reading “Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-893352","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCreative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Recent Issuance of U.S. Patents Covering ImmCelz\u2122 \u2014 Supercharged Regulatory T Cell Programs in Heart Failure and Type 1 Diabetes Reinforce Creative Medical\u2019s Similar Research Focus PHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (\u201cCreative Medical\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today congratulated Mary E. Brunkow, Ph.D., Fred Ramsdell, Ph.D., and Shimon Sakaguchi, M.D., Ph.D. on being awarded the 2025 Nobel Prize in Physiology or Medicine for foundational discoveries in peripheral immune tolerance and the biology of regulatory T cells (Tregs). Their work\u2014including the identification of Tregs and the central role of FOXP3\u2014reshaped modern immunology and catalyzed new treatment strategies across autoimmunity, transplantation, and cancer. In parallel with this … Continue reading "Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-07T14:25:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTExOSM3MTgyNzc3IzIwOTYxNzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs\",\"datePublished\":\"2025-10-07T14:25:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\\\/\"},\"wordCount\":768,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTExOSM3MTgyNzc3IzIwOTYxNzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\\\/\",\"name\":\"Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTExOSM3MTgyNzc3IzIwOTYxNzQ=\",\"datePublished\":\"2025-10-07T14:25:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTExOSM3MTgyNzc3IzIwOTYxNzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTExOSM3MTgyNzc3IzIwOTYxNzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/","og_locale":"en_US","og_type":"article","og_title":"Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs - Market Newsdesk","og_description":"Recent Issuance of U.S. Patents Covering ImmCelz\u2122 \u2014 Supercharged Regulatory T Cell Programs in Heart Failure and Type 1 Diabetes Reinforce Creative Medical\u2019s Similar Research Focus PHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (\u201cCreative Medical\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today congratulated Mary E. Brunkow, Ph.D., Fred Ramsdell, Ph.D., and Shimon Sakaguchi, M.D., Ph.D. on being awarded the 2025 Nobel Prize in Physiology or Medicine for foundational discoveries in peripheral immune tolerance and the biology of regulatory T cells (Tregs). Their work\u2014including the identification of Tregs and the central role of FOXP3\u2014reshaped modern immunology and catalyzed new treatment strategies across autoimmunity, transplantation, and cancer. In parallel with this … Continue reading \"Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-07T14:25:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTExOSM3MTgyNzc3IzIwOTYxNzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs","datePublished":"2025-10-07T14:25:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/"},"wordCount":768,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTExOSM3MTgyNzc3IzIwOTYxNzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/","name":"Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTExOSM3MTgyNzc3IzIwOTYxNzQ=","datePublished":"2025-10-07T14:25:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTExOSM3MTgyNzc3IzIwOTYxNzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTExOSM3MTgyNzc3IzIwOTYxNzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-congratulates-2025-nobel-laureates-for-regulatory-t-cell-breakthroughs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/893352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=893352"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/893352\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=893352"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=893352"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=893352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}